Inari Medical enrolls first patient in ClotTriever system trial for treating deep vein thrombosis
12 Jan 2023
Clinical Study
In August 2022, Inari Medical announced the launch of its Defiance trial for comparing ClotTriever to anticoagulation. Those enrolled in the trial (300 patients total) only have iliofemoral deep vein thrombosis (DVT). The trial spans 60 centers around the world.
Principal investigators Dr. Xhorlina Marko, Dr. Steven Abramowitz and Dr. Stephen Black lead the trial. Marko is based at Beaumont Health, Abramowitz at MedStar Health and Black at Guy’s and St. Thomas’ Hospital (London).
Dr. Abdullah Shaikh of Allegheny Health Network (Pittsburgh, Pennsylvania) enrolled the first patient. He said Inari and the investigators designed the trial to change the standard of care.
“We’re thrilled to enroll the first patient and officially kick off this important clinical trial,” said Shaikh. “ClotTriever is fundamentally different than other DVT treatments.”
Abramowitz added that Defiance should “answer critical questions” about DVT patient management. Prior trials focused on thrombolytic-based interventions, he noted. ClotTriever offers lytic-free thrombectomy to combat the downsides and limitations of previous treatments.
Inari Medical designed ClotTriever to capture and remove large clot burden from big vessels. Treating patients in one single session, it eliminates the need for thrombolytic and a stay in the intensive care unit.
“With six major clinical studies, including two ongoing RCTs, Inari is wholly committed to VTE patients and producing definitive evidence to support our technologies,” said Dr. Thomas Tu, Inari CMO. “None of this is possible without the collaboration and dedication of our clinical trial investigators who continually push the field forward in the name of better patient outcomes.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.